ANDA 74521, held by Hikma. Dipyridamole.
As of Nov 16, 2026, ANDA 74521 (Dipyridamole), held by Hikma, was first approved by FDA on Oct 18, 1996, with 8 approved supplements and 0 published complete response letters.
Indications and Usage Dipyridamole Injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately. In a study of about 1100 patients who underwent coronary arteriography and Dipyridamole Injection assisted thallium imaging, the results of both tests were interpreted blindly and the sensitivity and specificity of the dipyridamole thallium study in predicting the angiographic outcome were calculated. The sensitivity of the dipyridamole test (true positive dipyridamole divided by the total number of patients with positive angiography) was about 85%.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 1996 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dipyridamole5MG/ML · injectable;injection | Dipyridamole | Rx |
| Jun 4, 2026 | Supplement 25Manufacturing · Standard review | Approved | None posted |
| Jan 11, 2001 | Supplement 8Manufacturing | Approved | None posted |
| Apr 15, 1998 | Supplement 6Manufacturing | Approved | None posted |
| Sep 5, 1997 | Supplement 3Manufacturing | Approved | None posted |
| Sep 5, 1997 | Supplement 4Labeling | Approved | None posted |
| Sep 5, 1997 | Supplement 5Manufacturing | Approved | None posted |
| Apr 29, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Apr 29, 1997 | Supplement 2Manufacturing | Approved | None posted |
| Oct 18, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters